PT673258E - Derivados de camptotecina ligados a polimeros - Google Patents

Derivados de camptotecina ligados a polimeros

Info

Publication number
PT673258E
PT673258E PT94928387T PT94928387T PT673258E PT 673258 E PT673258 E PT 673258E PT 94928387 T PT94928387 T PT 94928387T PT 94928387 T PT94928387 T PT 94928387T PT 673258 E PT673258 E PT 673258E
Authority
PT
Portugal
Prior art keywords
pct
formula
camptothecin
units represented
hydroxy
Prior art date
Application number
PT94928387T
Other languages
English (en)
Portuguese (pt)
Inventor
Francesco Angelucci
Antonino Suarato
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of PT673258E publication Critical patent/PT673258E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
PT94928387T 1993-10-08 1994-09-21 Derivados de camptotecina ligados a polimeros PT673258E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939320781A GB9320781D0 (en) 1993-10-08 1993-10-08 Polymer-bound camptothecin derivatives

Publications (1)

Publication Number Publication Date
PT673258E true PT673258E (pt) 2003-09-30

Family

ID=10743226

Family Applications (1)

Application Number Title Priority Date Filing Date
PT94928387T PT673258E (pt) 1993-10-08 1994-09-21 Derivados de camptotecina ligados a polimeros

Country Status (24)

Country Link
US (1) US5773522A (https=)
EP (1) EP0673258B1 (https=)
JP (1) JPH08504217A (https=)
KR (1) KR100359005B1 (https=)
CN (1) CN1138565C (https=)
AT (1) ATE239507T1 (https=)
AU (1) AU679788B2 (https=)
CA (1) CA2150132A1 (https=)
DE (1) DE69432627T2 (https=)
DK (1) DK0673258T3 (https=)
ES (1) ES2198421T3 (https=)
FI (1) FI952746A7 (https=)
GB (1) GB9320781D0 (https=)
HU (1) HU215588B (https=)
IL (1) IL111173A (https=)
MY (1) MY116624A (https=)
NZ (1) NZ273952A (https=)
PL (1) PL178132B1 (https=)
PT (1) PT673258E (https=)
RU (1) RU2149646C1 (https=)
TW (1) TW316905B (https=)
UA (1) UA42706C2 (https=)
WO (1) WO1995010304A1 (https=)
ZA (1) ZA947823B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
DE19512484A1 (de) 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
CA2192725C (en) * 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
ATE210673T1 (de) * 1996-09-30 2001-12-15 Bayer Ag Glycokonjugate von modifizierten camptothecin- derivaten (20-o-verknüpfung)
DE19640969A1 (de) * 1996-10-04 1998-04-16 Bayer Ag 20-0-verknüpfte Glycokonjugate von Camptothecin
ID23424A (id) 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
GB9721070D0 (en) * 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Bioactive derivatives of camptothecin
GB9721069D0 (en) * 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
GB9915180D0 (en) * 1999-06-29 1999-09-01 Pharmacia & Upjohn Spa Antitumour compound
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
WO2001036002A1 (en) * 1999-11-17 2001-05-25 School Of Pharmacy, University Of London Conjugates of hpma copolymer and ellipticin
US20020077290A1 (en) * 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
GB0008928D0 (en) * 2000-04-11 2000-05-31 Pharmacia & Upjohn Spa A method of administering an antitumour compound
US6350756B1 (en) 2001-01-18 2002-02-26 California Pacific Medical Center Camptothecin derivatives
US6403604B1 (en) 2001-03-01 2002-06-11 California Pacific Medical Center Nitrogen-based camptothecin derivatives
US6855720B2 (en) 2001-03-01 2005-02-15 California Pacific Medical Center Nitrogen-based camptothecin derivatives
WO2003033525A1 (en) * 2001-10-12 2003-04-24 Debio Recherche Pharmacuetique S.A. Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
US6933302B2 (en) 2002-06-03 2005-08-23 California Pacific Medical Center Nitrogen-based homo-camptothecin derivatives
ITPD20050242A1 (it) * 2005-08-03 2007-02-04 Fidia Farmaceutici Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico
US7875602B2 (en) 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
CN101265331B (zh) * 2007-03-12 2010-10-13 中国科学院化学研究所 Peg改性phpma材料及其制备方法
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
DK2576638T3 (da) 2010-05-25 2021-03-15 Syndevrx Inc Polymerkonjugerede metap2-inhibitorer og terapeutiske fremgangsmåder til anvendelse deraf
CN105431426A (zh) 2013-04-10 2016-03-23 新德发制药有限公司 Metap2抑制剂和治疗肥胖症的方法
JP6529130B2 (ja) * 2013-08-26 2019-06-12 国立研究開発法人科学技術振興機構 接着剤
US9969722B2 (en) 2015-12-10 2018-05-15 Syndevrx, Inc. Fumagillol derivatives and polymorphs thereof
CN108697807B (zh) 2016-01-11 2021-11-26 辛德弗雷克斯公司 代谢功能障碍引起的肿瘤的治疗
CN113453721B (zh) 2018-10-26 2025-09-16 辛德弗雷克斯公司 Metap2抑制剂的生物标志物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
GB9309663D0 (en) * 1993-05-11 1993-06-23 Erba Carlo Spa Biologically active compounds

Also Published As

Publication number Publication date
AU7783694A (en) 1995-05-04
RU2149646C1 (ru) 2000-05-27
HU9502084D0 (en) 1995-09-28
DE69432627T2 (de) 2004-03-25
PL309328A1 (en) 1995-10-02
KR100359005B1 (ko) 2003-04-26
HU215588B (hu) 1999-01-28
DE69432627D1 (en) 2003-06-12
IL111173A0 (en) 1994-12-29
AU679788B2 (en) 1997-07-10
ZA947823B (en) 1995-07-03
NZ273952A (en) 1996-10-28
GB9320781D0 (en) 1993-12-01
IL111173A (en) 1998-10-30
EP0673258B1 (en) 2003-05-07
WO1995010304A1 (en) 1995-04-20
HUT71678A (en) 1996-01-29
CN1138565C (zh) 2004-02-18
RU95112841A (ru) 1997-06-27
PL178132B1 (pl) 2000-03-31
FI952746A0 (fi) 1995-06-05
ES2198421T3 (es) 2004-02-01
CN1115564A (zh) 1996-01-24
FI952746A7 (fi) 1995-06-05
MY116624A (en) 2004-03-31
UA42706C2 (uk) 2001-11-15
US5773522A (en) 1998-06-30
TW316905B (https=) 1997-10-01
CA2150132A1 (en) 1995-04-20
JPH08504217A (ja) 1996-05-07
EP0673258A1 (en) 1995-09-27
ATE239507T1 (de) 2003-05-15
DK0673258T3 (da) 2003-08-25

Similar Documents

Publication Publication Date Title
PT673258E (pt) Derivados de camptotecina ligados a polimeros
MX9408969A (es) Composisciones farmaceuticas que comprenden microparticulas biodegradables y biocompatibles para el tratamiento de transtornos psicoticos, su uso y procedimiento para prepararlas.
DE69021176D1 (de) Polypeptid und Verfahren zu dessen Herstellung.
MY109669A (en) N,o-sulphated heparosans, process for, preparing them and pharmaceutical compositions containing them
BG100951A (en) Novel erythromycin derivatives, method for their preparation and their use as drugs
ZA951653B (en) Ureido derivatives of naphthalenephosphonic acids and process for their preparation
TW354318B (en) Viscosity conditioner
EP0727391A3 (en) Polymeric salt of dithiocarbamic acid and method of use
EP0450420A3 (en) Dihydropyridines substituted by heterocycles, process for their preparation and their use in medicaments
DK0819132T3 (da) Fremgangsmåde til fremstilling af anthracyclin-antibiotika
IL109635A0 (en) Substituted arylcycloalkyl derivatives and pharmaceutical compositions containing them
PH24709A (en) Allylmercaptoacetylsydnonimines and pharmaceutical compositions thereof
IL108856A0 (en) Hydroxymethyl-furazancarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them
HU9403811D0 (en) Anthracycline conjugates, their preparation and their use as antitumor agents
CA2162899A1 (en) Polymeric thickeners for aqueous compositions
NZ315609A (en) 8-N-Anthrazalone derivatives
DE3362009D1 (en) L-alanyl-d-isoglutaminyl-adamantyl amide, process for its preparation and pharmaceutical compositions containing this compound
SG42910A1 (en) Benzopyrans
MY131175A (en) Heterocyclic compounds
CA2201096A1 (en) Solid dispersion and solid dispersion dosage form of xanthine derivative
AU4544096A (en) New derivatives of glycylanilides, preparation and therapeutical application
ES476077A1 (es) Un procedimiento para preparar derivados del acido 1,3-tia- zol-glioxilico.